Join to View Full Profile
7600 Shadywood RdBethesda, MD 20817
Phone+1 301-299-2922
Are you Dr. Helman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lee Helman, MD is an oncologist in Bethesda, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1980 - 1983
University of Maryland School of MedicineClass of 1980
Certifications & Licensure
MD State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsPhase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.Srivandana Akshintala, R Taylor Sundby, Donna Bernstein, John W Glod, Rosandra N Kaplan
Clinical Cancer Research. 2023-09-01 - 17 citationsThe Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.Joseph A Flores-Toro, Subhashini Jagu, Gregory T Armstrong, David F Arons, Gregory J Aune
Journal of Clinical Oncology. 2023-08-20 - 5 citationsA Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.John A Ligon, R Taylor Sundby, Mary F Wedekind, Fernanda I Arnaldez, Jaydira Del Rivero
Clinical Cancer Research. 2023-01-17
Press Mentions
Stand up to Cancer Announces $3.25 Million in Grants for Research to Improve Treatment of Head and Neck CancersJanuary 21st, 2021- Mithramycin Induces Promoter Reprogramming and Differentiation of Rhabdoid TumorDecember 17th, 2020
- Chemical Genomics Reveals Histone Deacetylases Are Required for Core Regulatory TranscriptionJuly 8th, 2020
- Join now to see all
